A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; HLX-10 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 22 May 2019 Planned number of patients changed from 24 to 30.
- 30 Apr 2019 Status changed from not yet recruiting to recruiting.
- 07 Dec 2018 New trial record